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Chemotherapy-induced nausea and vomiting (CINV) is a common side effect among cancer 
patients. The emetogenicity of chemotherapeutic agents is graded according to the expected rate of 
emesis without effective antiemetic prophylaxis; over 90 % of patients receiving highly emetogenic 
chemotherapy (HEC) and 30% to 90% receiving moderately emetogenic chemotherapy (MEC) 
would experience emesis. The occurrence of CINV is typically biphasic; thus, recommendations for 
antiemetic therapy are targeted to prevent CINV in the acute phase, occurring in the first 24 hours, or 
in the delayed phase, occurring later. Although 5-hydroxytryptamine receptor antagonists 
(5HT3-RAs) have significantly improved patients’ quality of life by preventing acute phase of CINV, 
these agents alone are insufficient in preventing CINV in the delayed phase even when administrated 
with corticosteroids.  
The novel neurokinin-1 (NK-1) receptor antagonist, aprepitant, is the first anti-emetics that prevent 
both acute and delayed CINV by blocking substance P in central nervous system. The efficacy of 
aprepitant, combined with 5HT3-RAs and dexamethasone, has been extensively studied and 
established in cisplatin-based regimen for malignant solid tumors. Accordingly, combination of 
5HT3-RAs, corticosteroids, and NK-1 antagonists has become standard of care for patients receiving 
HEC.  
The chemotherapeutic regimens for hematological malignancies have distinct features from those 
for solid malignancies. Firstly, chemotherapy regimens for hematological malignancies have much 
higher dose intensity comprising of multiple drugs and spanning for several days. Thus, it remains 
unclear whether the ordinal usage of aprepitant (125 mg on day 1 and 80 mg on day 2-5) is sufficient 
for the longstanding chemotherapies applied for hematological malignancies. Secondly, steroids are 
frequently included in hematological regimens in anticipation of antitumor effect, especially for 
lymphoid malignancies, and this makes it difficult for hematologists to use dexamethasone in 
anti-emetic protocols. Therefore, the effectiveness of aprepitant to prevent CINV in the settings 
without dexamethasone use should be assessed. Until now, several studies have demonstrated the 
benefit of incorporating aprepitant in antiemetic regimens for conditioning regimens for 
hematopoietic stem cell transplantation. However, little evidence was shown for aprepitant 
administration as antiemetic prophylaxis in conventional chemotherapies for hematological 
malignancies. To address these issues, I conducted a randomized controlled study to evaluate the 
efficacy of aprepitant in patients receiving chemotherapeutic agents for hematological malignancies.   
In this study, the patients who received conventional anti-emetic therapies were randomly allocated 
to either aprepitant or control groups. The aprepitant group received aprepitant for the first 5 days of 
treatments combined with 5HT3-RAs, and the control group received only 5HT3-RAs. Steroid was 
not included in the CINV prophylaxis unless included in the chemotherapeutic protocols. Comparing 
these two arms, I examined the efficacy of aprepitant in prevention of CINV for hematological 
chemotherapies. 
The primary endpoint of this study was the overall complete response (CR), which was defined as 
no emetic episodes or no administration of rescue medications during the first 10 days after the start 
of chemotherapies. Secondary endpoints were the rate of (1) no emesis, (2) no rescue medications, 
and (3) no significant nausea during the 10-day observation. Degree of nausea was measured daily 
with visual analog scale (VAS). Furthermore, actual oral intake, which has rarely been evaluated in 
the previous anti-emetics’ studies, was assessed by patients’ self-evaluation.  
Forty nine patients were enrolled in and 41 (22 patients in the aprepitant arm and 19 in the control 
arm) of them completed the study. There was no withdrawal due to the side effect of aprepitant.  
The overall CR was significantly better with aprepitant use. CR rate was 82% in the aprepitant arm 
and 47% in the control arm (p=0.026). Although there was no significant difference in CR rates in 
the acute phase (p=0.47), CR rate in the late phase tended to be more favorable in the aprepitant arm 
compared to the control arm (82% versus 58%, p=0.17). Emetic episodes during the overall 
observation period occurred less frequently in the aprepitant arm than in the control arm (9% versus 
42%, p=0.026). This result indicates that aprepitant suppressed emesis almost completely. In 
contrast, aprepitant did not reduce salvage anti-emetics use (p=0.47), nor level of nausea quantified 
by VAS. The self-reported oral intake revealed that almost 50% of the patients with aprepitant use 
maintained usual amounts of oral feeding throughout the observation period, whereas this rate 
dropped significantly to about 21% at day 6 among patients without aprepitant use. (p=0.049).  
With univariate analysis, underlying diseases (composed of “acute leukemia”, “malignant 
lymphoma”, and “multiple myeloma”; p=0.020) and chemotherapies (composed of “induction or 
consolidation for acute leukemia”, “platinum-based therapy”, and “auto HSCT conditioning 
regimen”; p=0.024) significantly affected CR rate. I conducted a multivariate analysis including the 
factor “use of aprepitant” fixed. Although none of the factors were significant, conditioning 
regimens for autologous transplantation were sub-significantly associated with a decreased response 
rate. In order to explore the traits that would potentially favor aprepitant use, I conducted sub-group 
analyses. Patients receiving chemotherapies for acute leukemia had little benefit from aprepitant 
(odds ratio (OR) = 0.74: 95% confidential interval (CI) = 0.03-29.4, p=1.0).  
Aprepitant succeeded in preventing vomiting in the overall period without severe side effects in 
our study. Although not statistically significant, patients with aprepitant use tend to have much more 
merit in the delayed phase than in the acute phase. Based on the fact that substance P is a major 
cause of CINV in the delayed phase, these findings are concordant with the mechanism of action of 
aprepitant, which selectively blocks binding of substance P to NK1 receptors of vomiting centers in 
the central nervous system.  
Among the various treatments included in this study, our results indicate that the additional effect 
of aprepitant was more prominent in the steroid containing regimens than in the steroid 
non-containing ones. This result can be partly explained by the difference in basal emetogenicity 
among the regimens. Concretely, higher CR rate was observed among the patients treated with 
steroid non-containing therapies compared to those with steroid containing (67% versus 38%) in the 
control arm. Steroid non-containing regimens mostly consisted of anthracycline and/or 
cytarabine-based chemotherapies for acute leukemia. This group of patients is recognized to have 
little merit from aprepitant administration. 
In the aprepitant arm, none of the patients who underwent autologous transplantation achieved CR 
and detailed analysis of this group indicated that all of the subjects suffered from late phase CINV. 
Thus, current strategy of aprepitant is not sufficient to control CINV for this group. 
In contrast to marked difference of emetic episodes between the two arms, aprepitant had little 
impact on preventing nausea. Similar results were also observed in other trials that assessed efficacy 
of aprepitant use in chemotherapies for solid tumors. Despite the fact that precise assessment is 
difficult, nausea should be controlled as well as emesis because it significantly impairs patients’ 
quality of life and motivation to receive further chemotherapies. It is interesting to note that 
olanzapine, an antipsychotic agent blocks multiple transmitters including dopamine, serotonin, and 
adrenergic receptors, is much more effective to control nausea in the delayed phase than aprepitant. 
It is not clarified whether the difference of target neurotransmitters can explain the different effect of 
aprepitant and olanzapine on nausea control.  
Daily oral food intake was self-assessed in this study. About 50% of the patients in the aprepitant 
arm maintained usual amounts of oral feeding throughout the observation period whereas this rate 
dropped significantly and only 21% had normal food intake in the control arm at day 6. However, 
generalized estimating equation analysis did not identify aprepitant as the significant factor for all 
observational period (pre-therapy oral intake impairment: β=39.1, p<0.001. aprepitant arm: β=0.107, 
p=0.78). Furthermore, I examined whether steroid-containing regimens had any effect on appetite, 
however, and found that this was not a significant factor to influence appetite (β=-0.662, p=0.16). 
Instead, degree of appetite loss was closely associated with nausea scale (p-value = 2.2x10-16, 
spearman’s rank test).  
The known adverse effects of aprepitant are hiccups, asthenia, and diarrhea, and rare but serious 
events include neutropenia. In this study, no patients experienced severe adverse events that were 
attributable to aprepitant. The safety profile highlights the merit of incorporating aprepitant in the 
anti-CINV prophylaxis.  
In conclusion, this is the first study to investigate the advantage of adding aprepitant to 
conventional 5HT3-RAs-based CINV prophylaxis in moderately/highly emetogenic chemotherapies 
for hematological malignancies. As I obtained sufficient anti-emetic effect without obvious adverse 
events, additional aprepitant use is recommendable. Further elucidation is required to establish the 
standard CINV prophylaxis for each chemotherapy regimen based on its individual efficacy profile. 
 
